RxDoctor Payments Data

Crystal Lagalle, DO

Internal Medicine · North Kansas City, MONPI 1891010666

Payments from drug & device makers

$5,518in general payments, 2019–2025

Across 330 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$801
  • AbbVie$734
  • Lilly USA, LLC$498
  • Boehringer Ingelheim$454
  • Amgen$374
  • Astellas Pharma US Inc$325
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,518 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$108,680
Medicare patients
364
Services billed
2,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$141,691
OzempicSemaglutide99$140,254
MounjaroTirzepatide49$83,436
FarxigaDapagliflozin Propanediol57$62,331
EliquisApixaban56$58,203
MyrbetriqMirabegron48$42,648
XareltoRivaroxaban19$30,946
TrulicityDulaglutide25$30,907
GemtesaVibegron23$23,812
JanuviaSitagliptin Phosphate16$23,024
AbrysvoRsv Vacc, Pref A And Pref B/Pf56$17,568
Tresiba Flextouch U-200Insulin Degludec13$15,026
Tresiba Flextouch U-100Insulin Degludec20$13,408
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$12,998
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$12,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta$454$166,423143 claims
Novo NordiskOzempic$294$140,25499 claims
Lilly USA, LLCMounjaro, Trulicity$498$114,34474 claims
PfizerEliquis, Abrysvo, Paxlovid$292$79,900128 claims
AstraZenecaFarxiga, Breztri Aerosphere$801$72,35471 claims
Astellas Pharma US IncMyrbetriq$325$42,64848 claims
Johnson & JohnsonXarelto$163$30,94619 claims
Sumitomo Pharma America, Inc.Gemtesa$64$23,81223 claims
MerckJanuvia$129$23,02416 claims
GSKShingrix, Arexvy$224$18,41678 claims
AbbVieSynthroid$734$4,83956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in North Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →